Viracta Therapeuticsの空売り状況は、投資家がViracta Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Viracta Therapeutics (OTC:VIRX) 株価情報, 空売り情報

Viracta Therapeutics

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

The Intergroup (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTG#NASDAQ">INTG</a>) reported quarterly losses of $(0.27) per share. This is a 81.25 percent increase over losses of $(1.44) per share from the same period last year. The company reported $16.82 million in sales this quarter. This is a 13.04 percent increase over sales of $14.88 million the same period last year.

Earnings

News

INTG

The Intergroup Q3 EPS $(0.27) Up From $(1.44) YoY, Sales $16.82M Up From $14.88M YoY

Intel Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) volume of processors it plans to produce for external customers using its <a target="_blank" href="https://www.benzinga.com/topic/chip-stocks" rel="noreferrer noopener">upcoming manufacturing technology</a> is insignificant, Reuters reported on Tuesday, citing CFO David Zinsner at JP Morgan&#8217;s Global Technology, Media and Communications conference.
The chipmaker struggled to progress with its 18A and latest 14A chip manufacturing technologies.
Zinsner told Reuters that the Intel foundry is on track to break even in 2027 and would require external customers to generate low to mid-single digit billions in revenue to accomplish that.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/04/45079217/intel-ramps-up-new-chip-tech-to-take-on-taiwan-semiconductors-global-lead" rel="noreferrer noopener">Intel Ramps Up New Chip Tech To Take On Taiwan Semiconductor&#8217;s Global Lead</a>
Intel stock plunged over 31% in the last 12 months. It failed to <a href="https://www.benzinga.com/media/25/04/45008023/intel-weighs-taiwan-semiconductor-partnership-to-boost-chip-game" target="_blank" rel="noreferrer noopener">capitalize on the</a> shift to artificial intelligence accelerators, similar to Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>). 
Intel fired its chief Pat Gelsinger in 2024 after his turnaround plan to take on Taiwan Semiconductor failed to impress the board. Intel struggled as rivals Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Nvidia captured market share in data centers, AI, and GPUs.
Intel reported <a target="_blank" href="https://www.benzinga.com/news/earnings/earnings-beats/25/04/45016595/intel-shares-slide-as-tariff-jitters-cloud-outlook-analysts-see-more-challenges-despite-new-ceo-initiatives" rel="noreferrer noopener">first-quarter revenue</a> of $12.7 billion, down 11% sequentially and 1% year-on-year, although it beat consensus of $12.2 billion. At the midpoint, the company guided to second-quarter revenue of $11.8 billion, significantly missing the consensus estimate of $12.8 billion.
Wall Street analysts cut their price targets on Intel after its first-quarter results, citing the beat as being driven by &#8220;customers purchasing ahead of potential tariffs,&#8221; which could impact demand in the second quarter. They also mentioned management concerns over an increasingly uncertain economic landscape.
Price Actions: On Thursday, INTC stock closed at $21.55.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45324239/apples-upcoming-chips-aim-to-challenge-meta-in-the-smart-glasses-battle-report" target="_blank" rel="noreferrer noopener">Apple&#8217;s Upcoming Chip Aims To Challenge Meta In Smart Glasses Battle: Report</a></li>
</ul>
Photo by Tupungato via Shutterstock

Tech

Media

INTC

NVDA

Intel CFO Says New Chip Output For Clients Will Be Minimal, Eyes Foundry Breakeven By 2027

Park Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKE#NYSE">PKE</a>) reported quarterly earnings of $0.12 per share. This is a 9.09 percent increase over earnings of $0.11 per share from the same period last year. The company reported $16.94 million in sales this quarter. This is a 3.71 percent increase over sales of $16.33 million the same period last year.

CORRECTION: Park Aerospace Q4 Adj. EPS $0.12 Up From $0.11 YoY, Sales $16.94M Up From $16.33M YoY

<a href="https://www.bloomberg.com/news/articles/2025-05-15/virgin-galactic-to-increase-price-for-space-tourism-flights?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-15/virgin-galactic-to-increase-price-for-space-tourism-flights?embedded-checkout=true</a>

General

SPCE

'Virgin Galactic to Increase Price for Space Tourism Flights'- Bloomberg

DSS (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DSS#AMEX">DSS</a>) reported quarterly losses of $(0.55) per share. This is a 5.17 percent increase over losses of $(0.58) per share from the same period last year. The company reported $4.95 million in sales this quarter. This is a 27.98 percent increase over sales of $3.87 million the same period last year.

DSS Q1 EPS $(0.55) Up From $(0.58) YoY, Sales $4.95M Up From $3.87M YoY

Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.27 by 40.74 percent. This is a 52 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $138.29 million which beat the analyst consensus estimate of $133.73 million by 3.41 percent. This is a 17.14 percent increase over sales of $118.06 million the same period last year.

Earnings Beats

DOCS

CORRECTION: Doximity Q4 Adj. EPS $0.38 Beats $0.27 Estimate, Sales $138.29M Beat $133.73M Estimate

NCRA

Nocera Q1 EPS $(0.0175) Up From $(0.0241) YoY, Sales $4.53M Down From $4.90M YoY

Blackboxstocks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBX#NASDAQ">BLBX</a>) reported quarterly losses of $(0.23) per share. This is a 14.81 percent increase over losses of $(0.27) per share from the same period last year. The company reported $587.08 thousand in sales this quarter. This is a 9.60 percent decrease over sales of $649.42 thousand the same period last year.

BLBX

Blackboxstocks Q1 EPS $(0.23) Up From $(0.27) YoY, Sales $587.08K Down From $649.42K YoY

Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) reported quarterly losses of $(0.14) per share. This is a 12.5 percent increase over losses of $(0.16) per share from the same period last year.

NNVC

Nanoviricides Q3 GAAP EPS $(0.14) Up From $(0.16) YoY

Innventure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) reported quarterly losses of $(3.10) per share which missed the analyst consensus estimate of $(0.11) by 2718.18 percent. The company reported quarterly sales of $224.00 thousand which missed the analyst consensus estimate of $600.00 thousand by 62.67 percent. This is the same as the same period last year.

Earnings Misses

Innventure Q1 EPS $(3.10) Misses $(0.11) Estimate, Sales $224.00K Miss $600.00K Estimate

LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) reported quarterly losses of $(0.12) per share. This is a 99.44 percent increase over losses of $(21.25) per share from the same period last year. The company reported $2.59 million in sales this quarter. This is a 0.73 percent decrease over sales of $2.61 million the same period last year.

LGMK

LogicMark Q1 GAAP EPS $(0.12) Up From $(21.25) YoY, Sales $2.59M Down From $2.61M YoY

SUNE

SUNation Energy Q1 EPS $(106.71) , Sales $12.64M Down From $13.22M YoY

Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) reported first-quarter financial results after the market close on Thursday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/n45451173/quantum-computing-inc-reports-first-quarter-2025-financial-results">of the report</a>.
Q1 Earnings: Quantum Computing reported first-quarter revenue of $39,000, missing analyst estimates of $100,000, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported first-quarter earnings of 11 cents per share, beating estimates for a loss of seven cents per share.
&#8220;We&#8217;re encouraged by our early traction, which is the first step in what we believe is a significant, multi-year opportunity to serve the expanding markets in datacom, telecom and quantum-enabled applications,&#8221; said Yuping Huang, CEO of Quantum Computing Inc.
&#8220;In parallel, we continued to deepen engagement with both government and commercial partners, reinforcing the growing interest in our quantum and photonic machines and positioning QCi to capitalize on emerging opportunities ahead.&#8221;
The company said it completed construction of its Quantum Photonic Chip Foundry in Tempe, Arizona, during the first quarter. The company also highlighted a subcontract awarded subsequent to the quarter&#8217;s end through Analytical Mechanics Associates to support NASA&#8217;s Langley Research Center. The subcontract is valued at approximately $406,000.
QUBT Price Action: <a href="http://benzinga.com/quote/qubt">Quantum Computing Inc shares</a> were up 1.62% after-hours, trading at $9.24 at the time of publication on Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45449426/whats-going-on-with-d-wave-quantum-shares-this-month">What&#8217;s Going On With D-Wave Quantum Shares This Month?</a></li>
</ul>
Photo: Bartlomiej K. Wroblewski/Shutterstock.

Movers

QUBT

Quantum Computing Inc Reports Q1 Earnings, Shares Move Higher After Hours

Binah Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCG#NASDAQ">BCG</a>) reported quarterly earnings of $0.06 per share. This is a 142.86 percent increase over losses of $(0.14) per share from the same period last year. The company reported $48.94 million in sales this quarter. This is a 18.06 percent increase over sales of $41.45 million the same period last year.

CORRECTION: Binah Capital Group Q1 EPS $0.06 Up From $(0.14) YoY, Sales $48.94M Up From $41.45M YoY

Mobiquity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBQ#NASDAQ">MOBQ</a>) reported quarterly losses of $(0.12) per share. This is a 50 percent increase over losses of $(0.24) per share from the same period last year. The company reported $12.61 thousand in sales this quarter. This is a 95.21 percent decrease over sales of $263.28 thousand the same period last year.

MOBQ

Mobiquity Technologies Q1 GAAP EPS $(0.12) Up From $(0.24) YoY, Sales $12.61K Down From $263.28K YoY

VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) reported quarterly losses of $(0.06) per share. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported $246.38 thousand in sales this quarter. This is a 43.64 percent increase over sales of $171.53 thousand the same period last year.

VNRX

VolitionRX Q1 EPS $(0.06) Up From $(0.10) YoY, Sales $246.38K Up From $171.53K YoY

Offerings

LOAR

Loar Holdings Files For Offering Of 9M  Shares Of Common Stock By Selling Stockholders

Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) anticipate consolidated Q2 revenue to remain in line with the Q1 2025

Guidance

FLNT

Fluent anticipate consolidated Q2 revenue to remain in line with the Q1 2025

Highlights
<ul>
<li>Transaction includes approximately 2,600 megawatts of modern natural gas generation assets at an attractive price of approximately $743/kW of capacity.</li>
<li>Acquisition is expected to deliver Ongoing Operations AFCFbG1 accretion in year one following closing.</li>
<li>Reiterating previously communicated capital allocation plan, including long-term net leverage target of less than 3x2, the expected return of capital to shareholders by way of the planned $300 million in annual dividends and at least $1 billion of share repurchases each year.</li>
</ul>
IRVING, Texas, May 15, 2025 /PRNewswire/ -- Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) today announced that it has executed a definitive agreement to acquire seven modern natural gas generation facilities, totaling approximately 2,600 MW of capacity, from Lotus Infrastructure Partners ("Lotus"). The acquisition includes five combined cycle gas turbine facilities and two combustion turbine facilities located across PJM, New England, New York, and California, further geographically diversifying Vistra's natural gas fleet.
 &nbsp;

Vistra To Acquire 2,600 Megawatts Of Modern Natural Gas Assets From Lotus For $743/kW

FIHL

Fidelis Insurance Holdings Files For Mixed Shelf; Size Not Disclosed

Press Releases

Viracta Therapeutics Announces New Employment Inducement Grants

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Comments

Viracta Therapeutics

空売り

Viracta Therapeutics (OTC:VIRX) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル